tirzepatide summit Helps in HFpEF Across Spectrum of Obesity Severity 🧬 New data from the
Pay in 4 interest-free payments of $6.17 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
New data from the SUMMIT trial reveals that long term tirzepatide (Zepbound) may significantly improve kidney function in patients with obesity, chronic kidney disease (CKD), and heart failure with preserved ejection fraction ( Another "Positive" Heart Failure Trial that Falls Short Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM The SUMMIT trial @AHAScience Summary Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial JACC Tirzepatide Reduces Risk of Heart Failure Outcomes in Adults with HFpEF and Obesity: Phase 3 SUMMIT Trial Patient Care Online Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https: t.co 8joe2mst3e Editorial: Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction https: t.co hpmbSDk76L #Cardiology
Store: skntheory.com · Domain: skntheory.com







.png)


















